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E-mail address: christa.buechler@klinik.uni-regensAdiponectin whose systemic levels are reduced in obesity-related diseases ameliorates insulin sen-
sitivity and regulates biological processes like apoptosis, proliferation, migration and inﬂammation.
Adiponectin binds to adiponectin receptors, AdipoR1 and AdipoR2, which are ubiquitously
expressed. Clathrin-dependent endocytosis of AdipoR1 and adiponectin has been demonstrated to
modulate adiponectin bioactivity. Recently, APPL1 has been identiﬁed as an AdipoR1 and AdipoR2
binding protein. Furthermore, activated protein kinase C1, endoplasmic reticulum protein 46 and
protein kinase CK2b subunit form a complex with AdipoR1. This review summarizes recent studies
exploiting heterologous expression of adiponectin receptors in yeast, and the type and function of
the recently described adiponectin receptor associated proteins.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Adiponectin (AdipoQ, Acrp30, apM1) is an adipose tissue de-
rived hormone of the C1q/TNF-superfamily which is highly abun-
dant in human serum and shows an inverse correlation with
body mass index [1]. Adiponectin ameliorates insulin sensitivity
and higher adiponectin levels are associated with a lower risk for
type 2 diabetes inWhites, East Asians, Asian Indians, African Amer-
icans, and Native Americans [2,3]. Adiponectin circulates as trimer,
hexamer and higher-order multimer (HMW) in serum, and iso-
form-speciﬁc effects have been described [4,5]. The HMW form is
the major active form mediating the insulin-sensitizing effects of
adiponectin [2,5,6]. Impaired multimerization of adiponectin in
humans is associated with type 2 diabetes mellitus showing that
higher-order multimeric structures are important for the biological
function of this adipokine [6].
Globular adiponectin, the globular C1q domain of adiponectin
generated by proteolysis of the full-length protein, is also biologi-
cally active [7]. However, circulating levels seem to be rather low
questioning the biological signiﬁcance of this protein [8] that
may nevertheless be of therapeutical interest. Adiponectin may
also form heterooligomers with additional members of the C1q/
TNF-related protein (CTRP) family like the recently described
CTRP9 [9] but the physiological role of such complexes has not
been evaluated so far.chemical Societies. Published by E
burg.de (C. Buechler).Two 7-transmembrane proteins, AdipoR1 and AdipoR2, have
been identiﬁed to function as adiponectin receptors [10]. Protein
sequence alignment reveals that the N-terminal 69 amino acids
of AdipoR1 and the 79 aa of AdipoR2 are speciﬁc for each recep-
tor whereas the rest of these proteins is highly homologous (80%
identity). Initial studies demonstrate that both receptors are
integral membrane proteins with an internal N-terminus and
an external C-terminus, which is opposite to the topology of
G-protein coupled receptors [10]. T-cadherin binds hexameric
and HMW adiponectin in endothelial and smooth muscle cells
[11,12]. However, T-cadherin is a glycosylphosphatidylinositol-
anchored protein, and therefore, has to interact with a yet not
identiﬁed transmembrane receptor protein for signal transduc-
tion [12].
Besides its multiple peripheral effects adiponectin may ame-
liorate insulin resistance by acting in the brain, and intracerebro-
ventricular administration of adiponectin in rodents decreases
body weight by stimulating energy expenditure [13]. Adiponec-
tin most likely crosses the blood-CSF-barrier (BCB) and/or the
blood-brain barrier (BBB) [14,15] and is about 1000-fold lower
concentrated in human cerebrospinal ﬂuid (CSF) than in serum
[8,14,15]. Similar to systemic adiponectin, CSF adiponectin is
higher in females [15] and the trimeric and hexameric isoforms
are predominantly found in human CSF [8]. AdipoR1 and Adi-
poR2 protein are expressed in the hypothalamus and the para-
ventricular nucleus further indicating that adiponectin exerts a
speciﬁc role in the brain [14].
AdipoR1 and AdipoR2 exert similar effects but also have
individual signalling preferences. Whereas phosphorylation oflsevier B.V. All rights reserved.
Fig. 1. Clathrin-dependent endocytosis of adiponectin and AdipoR1. Clathrin-
dependent constitutive endocytosis of AdipoR1 depends on Rab5. Adiponectin co-
localizes with internalized AdipoR1 indicating similar uptake pathways. Whether
these proteins are degraded in the lysosome has not been analysed so far. Blockage
of endocytic uptake stimulates basal and adiponectin-mediated phosphorylation of
C. Buechler et al. / FEBS Letters 584 (2010) 4280–4286 4281extracellular regulated kinase 1/2 may depend on both receptors,
AdipoR1 is more prominent in AMP-activated protein kinase
(AMPK) phosphorylation, and AdipoR2 is involved in PPARa activa-
tion [10,16,17]. How the signals are transduced from the adiponec-
tin receptors to downstream molecules, however, remains largely
unknown. So far adaptor protein containing pleckstrin homology
domain, phosphotyrosine binding (PTB) domain and leucine zipper
motif 1 (APPL1), endoplasmic reticulum protein 46 (ERp46), acti-
vated protein kinase C1 (RACK1) and protein kinase CK2b subunit
(CK2b) have been identiﬁed to directly interact with adiponectin
receptors and their role has been mainly studied for AdipoR1 sig-
nalling. This review article will give a short summary on the iden-
tiﬁcation and function of adiponectin receptor associated proteins.
2. Progestin and AdipoQ receptor family
AdipoR1 and AdipoR2 belong to the recently described proges-
tin and AdipoQ receptor (PAQR) family named after the two ini-
tially described ligands, progestin and adipoQ [18]. The eleven
proteins currently identiﬁed as PAQR family members have a con-
served structure/topology with invariant intracellular amino acid
residues [18].
These proteins are grouped into three classes based on se-
quence similarities. Class I receptors are expressed in nearly all
eukaryotes with the most prominent members AdipoR1 (PAQR1)
and AdipoR2 (PAQR2). Class II proteins are non-classical receptors
for the steroid hormone progesteron including mPRa (PAQR7). The
most diverged family members are the class III members PAQR10
and -11 where no agonist has been identiﬁed yet [18].
3. Heterologous expression of AdipoR1 and AdipoR2 in yeast
Kupchak et al. have demonstrated that overexpression of Adi-
poR1 in yeast alone is sufﬁcient to induce downstream signalling
whereas AdipoR2 is not active until stimulated with adiponectin.
Downstream molecules in yeast are RAS2 (RAS GTPase family
member), TPK1 (catalytic subunit of cAMP-dependent protein ki-
nase, isoform 1), TPK2 (TPK isoform 2), TPK3 (TPK isoform 3),
SIP1 (Snf1 Ser/Thr-speciﬁc protein kinase beta subunit), SNF4
(Snf1 protein kinase gamma subunit), SIP3 (activator of transcrip-
tion related to Snf1), NRG1 (transcriptional repressor that func-
tions in glucose repression of a subset of Snf1-regulated genes)
and NRG2 for both receptors [19,20]. Snf1 is the yeast homolog
of mammalian AMP-activated protein kinase (AMPK), and involved
in nutrient sensing in lower organisms [19].
Basal and agonist-induced signalling of AdipoR1 and agonist-in-
duced signalling of AdipoR2 are blocked by a ceramidase inhibitor
indicating that sphingoid base second messengers are involved in
signal transduction [20]. Ceramides are generated in several tis-
sues and cells upon lipopolysaccharide and TNF stimulation and
excess ceramide may contribute to insulin resistance [21,22].
TNF, which is like adiponectin a member of the C1q/TNF protein
family [23], antagonizes AdipoR1 and AdipoR2 activity in yeast,
but this blockade seems to be independent of downstream signal-
ling pathways [20].
4. Endocytosis of AdipoR1
Surface receptor activity may be shut down by endocytic uptake
and subsequent lysosomal degradation of the proteins [20]. Clath-
rin-dependent endocytosis (CDE) has been extensively studied and
internalization from the plasma membrane is mediated through
clathrin-coated pits and vesicles, and ubiquitination-dependent
delivery into endosomal vesicles [24]. Cells may internalize the
equivalent of their cell surface one to ﬁve times per hour [25],and therefore, the removal of plasma membrane proteins and lip-
ids is counterbalanced by recycling pathways.
Endocytic receptor uptake is either stimulated by ligand bind-
ing or is a constitutive and ligand-independent process. Different
endocytotic pathways may be involved in the internalization of a
speciﬁc receptor protein with distinct biological responses. For in-
stance uptake of transforming growth factor b (TGF-b) receptor via
CDE promotes signalling whereas caveolin-mediated uptake regu-
lates receptor turnover [26].
AdipoR1 and AdipoR2 are predicted to be located at the plasma
membrane [10]. Besides residing at the plasmamembrane AdipoR1
and AdipoR2 are also distributed in the cytoplasma with AdipoR1
being located in cytoplasmic puncta [27]. Overexpression of C-ter-
minally myc-tagged AdipoR1 in Hek293 cells was employed to
study protein internalization which starts within 5 min and is
completed 30–60 min later. Recombinant full-length adiponectin
is taken up by cells as has been demonstrated for hepatocytes,
epithelial cells and HeLa cells [27–29]. Globular adiponectin, the
globular C1q domain of adiponectin generated by proteolysis of
the full-length protein is also internalized by HeLa cells [27]. In
contrast baculovirus-produced trimeric adiponectin [30] is not
incorporated by hepatocytes (own unpublished observation).
Adiponectin colocalizes with AdipoR1 indicating similar trafﬁcking
routes of both proteins (Fig. 1). Exogenously provided adiponectin
does not inﬂuence endocytosis of AdipoR1 suggesting ligand-inde-
pendent internalization. Colocalization of endocytosed adiponectin
and AdipoR1 with transferrin and the transferrin receptor surmise
clathrin-mediated uptake of adiponectin and AdipoR1. This is fur-
ther proven by overexpression of Eps15 mutants, potassium deple-
tion and hypertonic medium that all inhibit CDE and AdipoR1
internalization [27].
The small GTPase Rab5 plays an important role in the formation
and dynamics of early/sorting endosomes [31]. Colocalization of
AdipoR1 and Rab5 and blockage of AdipoR1 endocytosis by a dom-
inant-negative Rab5 mutant conﬁrms a critical role of Rab5 in Adi-
poR1 uptake [27].
Blocking endocytosis of AdipoR1 enhances adiponectin stimu-
lated phosphorylation of AMPK and acetyl-CoA carboxylase
(ACC). Whether this is explained by higher plasma membrane
levels of AdipoR1 has not been evaluated so far. In addition basalAMPK and ACC.
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cytosis of AdipoR1 is inhibited [27] (Fig. 1). Overexpression of Adi-
poR1 in yeast is sufﬁcient to stimulate ligand-independent
signalling [32], and additional studies have to prove if similar
mechanisms are responsible for this effect. In conclusion, clath-
rin-dependent endocytosis of AdipoR1 seems to downmodulate
adiponectin signalling.Fig. 2. Function of APPL1 in AdipoR1 signalling. APPL1 forms a complex with
AdipoR1 and knock-down of APPL1 impairs adiponectin-mediated phosphorylation
of AMPK and p38 MAPK. GLUT4 plasma membrane translocation is induced.
Whether the AdipoR1-APPL1 complex is localized at the plasma membrane has not
been conﬁrmed yet. Adiponectin stimulates AMPK by promoting the nuclear export
of LKB1 that subsequently binds to APPL1 to stabilize cytosolic localization.
Adiponectin also activates Ca2+/calmodulin-dependent protein kinase (CaMKK) by
phospholipase C (PLC)-mediated Ca2+ increase. LKB is the major AMPK kinase
whereas CaMKK seems to play a minor role in AMPK phosphorylation. Adiponectin
furthermore increases extracellular Ca2+ inﬂux and subsequent activation of AMPK,
whether APPL1 is involved herein has not been analysed so far.5. APPL1 stimulates AdipoR1 signalling
Recently, APPL1 has been identiﬁed as an AdipoR1 and AdipoR2
binding protein. The N-terminal amino acids (4–142) of AdipoR1
interact with the phosphotyrosine binding domain (PTB) of APPL1
whereas its pleckstrin homology domain and the Bin-amphiphy-
sin-Rvs (BAR) domain are dispensable for this association. The for-
mation of the AdipoR1 APPL1 complex is enhanced by adiponectin
[33]. APPL1 is highly abundant in mouse skeletal muscle and dif-
ferentiated C2C12 myotubes and moderately expressed in hepato-
cytes [33].
Overexpression of APPL1 in C2C12 myotubes is associated with
increased basal and adiponectin-stimulated phosphorylation of
AMPK and p38 MAPK whereas small interference RNA-mediated
suppression of APPL1 impairs adiponectin-stimulated phosphory-
lation of AMPK, p38 MAPK and ACC [33]. Knock-down of APPL1
is even associated with a reduced expression of AMPK protein indi-
cating that APPL1 may be a crucial adaptor protein in metabolic
control besides its role in adiponectin signalling [33].
AMPK is a serine/threonine protein kinase composed of a cata-
lytic a subunit with the activating phosphorylation site (Thr172)
and two regulatory subunits, b and c. The two AMPK variants, a1
and a2, show different cellular localization in mammalian cells.
AMPKa2 is detected in nuclear and non-nuclear fractions whereas
AMPKa1 is only found in the latter. An increase in AMP leads to the
binding of AMP to the c subunit, subsequent conformational
changes of the AMPK heterotrimer and AMPK activation.
Phosphorylation by the upstream kinases, LKB1 and Ca2+/calmodu-
lin-dependent protein kinase kinase (CaMKK) increase AMPK
activity [34]. Adiponectin stimulates translocation of LKB1 from
the nucleus to the cytosol. APPL1 enhances cytosolic localization
of LKB1 by interacting with this kinase via its BAR domain thereby
facilitating phosphorylation of AMPK [35] (Fig. 2). Interestingly, the
antidiabetic drug metformin also stimulates cytosolic localization
of LKB1 and thereby may increase AMPK phosphorylation.
CaMKK is another upstream kinase of AMPK that phosphory-
lates AMPK independent of AMP levels. Adiponectin induces Ca2+
release from the endoplasmic reticulum by activating phospholi-
pase C thereby stimulating CaMKK mediated phosphorylation of
AMPK. This pathway is independent of LKB1 and APPL1 and seems
to play a minor role in adiponectin mediated activation of AMPK
[35].
In myocytes adiponectin via binding to AdipoR1 also stimulates
extracellular Ca2+ inﬂux and subsequent activation of CAMKK and
AMPK (Fig. 2) [36]. AMPK in concert with sirtuin 1 (SIRT1) promote
phosphorylation and deacetylation of peroxisome proliferator-
activated receptor y coactivator-1a (PGC-1a), thereby enhancing
PGC-1a activity. Muscle-speciﬁc AdipoR1 knock-out mice display
decreased PGC-1a, lower number of mitochondria, reduced type I
ﬁbres and lower exercise capacity [36]. However, whether APPL1
is involved herein has not been analysed so far.
Full-length and globular adiponectin promote translocation of
GLUT4 to the plasma membrane. Similar effects are observed in
cells where APPL1 is overexpressed whereas recombinant expres-
sion of APPL1 lacking the PTB domain impairs adiponectin-induced
GLUT4 membrane translocation. The N-terminal BAR domain of
APPL1 binds activated Rab5 and adiponectin induces the formationof this complex. Adiponectin stimulated GLUT4 membrane translo-
cation is blocked by dominant-negative Rab5 and by APPL1 devoid
of its BAR domain [35].
6. APPL2 down-modulates AdipoR1 signalling
APPL2 is an APPL1 isoform with 54% identity in protein se-
quence and similar protein domain organization [37]. APPL2 binds
to AdipoR1 and AdipoR2, and in addition forms heterodimers with
APPL1 via an interaction of their BAR domains [38]. APPL2 nega-
tively regulates AdipoR1-dependent signalling in C2C12 cells
exploiting two distinct mechanisms: ﬁrstly APPL2 competes with
APPL1 for the binding to AdipoR1, and secondly APPL2 anticipates
APPL1 binding to AdipoR1 by forming a heterodimer with APPL1
(Fig. 3). The biguanide metformin as well as adiponectin promote
dissociation of the APPL1/APPL2 complex and translocation of
cytosolic APPL1 to the plasma membrane. Adiponectin further-
more stimulates disruption of the AdipoR1/APPL2 complex thus
enabling binding of APPL1 [38] (Fig. 3).
7. Involvement of APPL1 in adiponectin-stimulated ERK1/2
phosphorylation
Adiponectin activates the ERK1/2 MAP kinase pathway in vas-
cular smooth muscle cells, endothelial cells, Hek293 cells, macro-
phages and hepatocytes [16,39,40]. Nevertheless, suppression of
ERK1/2 by adiponectin has also been demonstrated [41,42] and
currently there is no simple explanation for these discrepant ﬁnd-
ings. While AdipoR1 seems to be important for ERK1/2 activation
in hepatocytes [39], AdipoR2 is involved in ERK1/2 activation in
the granulosa tumour cell line KGN [43] and both receptors
stimulate ERK1/2 in Hek293 cells [16]. Some studies conﬁrmed
RNAi-mediated knock-down of AdipoR1 or AdipoR2 at the mRNA
but not the protein level, and therefore, the different levels of
protein reduction might partly explain the contradictory ﬁndings
[16,39,43].
Lee et al. have demonstrated that APPL1 associates with
AdipoR1 in Hek293 cells where both proteins have been
Fig. 3. APPL2 antagonizes AdipoR1 signalling. (A) Binding of APPL2 to AdipoR1 and
APPL1 blocks the formation of AdipoR1–APPL1 complexes. (B) Adiponectin induces
the dissociation of AdipoR1–APPL2 and APPL1–APPL2 complexes thereby enabling
binding of APPL1 to AdipoR1.
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the formation of this complex is not enhanced by exogenous
adiponectin [16,33]. Knock-down of APPL1 reduces the level of
adiponectin-stimulated ERK1/2 phosphorylation thereby proving
that APPL1 is involved [16].8. Involvement of APPL1 in adiponectin-stimulated cell survival
and nitric oxide production
Adiponectin is reported to promote cell survival and growth but
may also stimulate apoptosis [30,41,42,44,45]. IL-18 mediated
endothelial cell death is blocked by adiponectin by a pathway
involving APPL1-dependent AMPK activation [45].
Endothelial dysfunction is closely associated with an impaired
production of nitric oxide (NO) and adiponectin protects the
vascular system through stimulation of endothelial NO synthase
(eNOS). In human umbilical vein endothelial cells (HUVECs) both
adiponectin receptors mediate NO production [46] whereas
knock-down of either AdipoR1 or AdipoR2 has no effect. Whether
this indicates that an individual receptor is not effective or simply
reﬂects insufﬁcient knock-down of the receptors needs further
investigation [45]. Pull-down assays using GST-tagged N-terminal
fragments of the adiponectin receptors and subsequent tandem
mass spectrometry analysis revealed that phosphatase 2A, rabe-
nosyn-5, striatin, regulator of G-protein signalling 4 and APPL1
may be associated with both receptors. The interaction of APPL1
with the receptors has been conﬁrmed by co-immunoprecipita-
tion and is slightly enhanced by adiponectin. The PTB domain
of APPL1 is involved in complex formation with AdipoR1 and Adi-
poR2 [45].
RNAi-mediated suppression of APPL1 in HUVECs blocks adipo-
nectin-stimulated association of heat shock protein 90 with eNOS
which is essential for maximal eNOS activity. Furthermore, adipo-
nectin mediated phosphorylation of AMPK and eNOS and subse-
quent NO production are impaired [45].9. Adiponectin receptor forms a complex with APPL1 in the
hypothalamus
Besides its multiple peripheral actions adiponectin may exert
central effects, and intracerebroventricular (icv) administration of
adiponectin in rodents decreases body weight by stimulating en-
ergy expenditure and fatty acid oxidation [13]. Furthermore, icv-
injected adiponectin reduces food intake by about 40% in fasted
rats [47]. Hypothalamic-expressed AdipoR1 and AdipoR2 are asso-
ciated with APPL1 [47]. Adiponectin enhances AMPK activity in the
arcuate nucleus of the hypothalamus (ARH) via AdipoR1 [47,48]
but whether APPL1 acts upstream of central AMPK activation has
not been demonstrated so far.
10. APPL1 is located at signalling endosomes
APPL1 has been initially identiﬁed as an Akt2-binding protein
and may also associate with PI3K subunits. APPL1 knock-down im-
pairs insulin-induced Akt phosphorylation and glucose uptake.
APPL1 is an adaptor protein involved in multiple pathways and
complex formation with various proteins has been described and
is summarized in a very recent review article [49].
Furthermore, there is emerging evidence that endocytic path-
ways are directly involved in signalling. Endosomal compartments
function as mediators of epidermal growth factor (EGF) signalling
between the plasmamembrane and the nucleus [37]. This pathway
involves Rab5, APPL1 and APPL2, localized to distinct endocytic
compartments. After EGF uptake the GTPase cycle of Rab5 deter-
mines the release of APPL1 from the endosomal membrane. APPL1
translocates to the nucleus and interacts with the nucleosome
remodelling and histone deacetylase complex NuRD/MeCP1, and
thereby stimulates cell proliferation [37].
Furthermore APPL1 forms a complex with the PDZ protein Gaip
C-terminus interacting protein (GIPC) and recruitment of GIPC by
APPL1 to endosomes is essential for tyrosine kinase receptor A
(TrkA) trafﬁcking and signalling [50].
Whether similar mechanisms play a role in adiponectin signal
transduction and whether additional proteins are recruited to
adiponectin receptors via APPL1 has not been analysed so far.
Although it has been clearly established that APPL1 is a down-
stream adaptor protein in adiponectin signal transduction, the cel-
lular localization of the AdipoR1/APPL1 complex has not been
characterized yet. APPL1 is found at the plasma membrane and
in early endosomes localized close to the plasma membrane and
adiponectin seems not to stimulate APPL1 translocation to the
membrane [33].11. AdipoR1 forms a complex with activated protein kinase C1
in hepatocytes
Screening of a liver cDNA library with full-length AdipoR1 as
bait employing the yeast two-hybrid system identiﬁed activated
protein kinase C1 (RACK1) as a potential binding protein [51].
The association has been conﬁrmed by co-immunoprecipitation
with FLAG-tagged RACK1 and Myc-tagged AdipoR1 co-expressed
in COS-7 cells. Recombinant expressed DsRed2-RACK1 displays
cytoplasmic localization and GFP-AdipoR1 is predominantly de-
tected at the plasma membrane. Incidental co-localization of Adi-
poR1 and RACK1 in the cell membrane is strongly enhanced by
exogenous adiponectin within 30 min of incubation. Knock-down
of RACK1 in HepG2 cells impairs adiponectin stimulated glucose
uptake [51].
RACK1 is a cytosolic scaffold protein composed of seven WD40
motifs that may associate with distinct proteins [52]. RACK1 is a
constituent of the eukaryotic ribosome, and recruits activated
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others an interaction of RACK1 with protein kinase C, Src kinases
and the p85 subunit of PI3 kinase and SHP-2 has been conﬁrmed
[54,55]. Receptors that bind to RACK1 include insulin-like growth
factor 1 receptor, type II bone morphogenetic protein receptor
and multidrug resistance protein 3 (MDR3/ABCB4) [56–58]. Inter-
estingly, adiponectin and metformin reduce ABCB4 abundance in
hepatocytes although different mechanisms seem to be involved
[44,59]. Whether this may allow enhanced recruitment of RACK1
to AdipoR1, however, needs further investigation.
12. AdipoR1 forms a complex with protein kinase CK2b subunit
in C2C12 and MCF7 cells
The N-terminal 136 aminoacids of AdipoR1 have been used to
screen a testis cDNA yeast-two-hybrid library and identiﬁed pro-
tein kinase CK2 b subunit (CK2b) [60]. Immunoprecipitation of
the AdipoR1 N-terminus or the whole receptor expressed as EYFP
fusion protein in the breast cancer cell line MCF7 has been per-
formed using antibodies against the tag. Coimmunoprecipitation
of CK2b with AdipoR1 is only observed after cross-linking the pro-
teins, and therefore, the complex may be either unstable in the
experimental settings used or short-lived in vivo [60]. The region
of CK2b that binds to AdipoR1 was mapped to the aminoacid-posi-
tion 113–119 (GHRPPMP) encoding a putative Src homology 3 do-
main (SH3) [60]. This sequence is conserved in AdipoR2 but
complex formation of AdipoR2 and CK2b has not been studied so
far.
AdipoR1 (EYFP-tagged) and CK2b (HA-tagged) have been ex-
pressed in Hek293 cells, and AdipoR1 is predominantly distributed
in the cell membrane and CK2b in the cytoplasma. Little co-locali-
zation is observed until addition of exogenous adiponectin that
stimulates localization of CK2b to the membrane and its co-locali-
zation with AdipoR1 [60].
When CK2 activity is blocked by the speciﬁc inhibitor 2-dimeth-
ylamino-4,5,6,7-tetrabromo-1H-benz-imidazole (DMAT) adiponec-
tin-induced phosphorylation of ACC is reduced in C2C12 and MCF7
cells. Inhibition of CK2 with DMAT alone also increases ACC phos-
phorylation, indicating an adiponectin-independent inﬂuence of
CK2 in the regulation of ACC phosphorylation [60].
CK2b is the regulatory subunit of the protein serine/threonine
kinase CK2. CK2 is involved in cellular processes such as prolifera-
tion, apoptosis and differentiation. CK2b has been identiﬁed to
interact with various proteins like G-alpha subunits to inhibit G
protein-coupled receptor activity, with the hemoglobin-haptoglo-
bin scavenger receptor CD163 to stimulate signalling and with
p38 MAPK to allosterically activate CK2 in cellular stress situations
[61–63].
13. Endoplasmic reticulum protein 46 (ERp46) binds to AdipoR1
in HeLa cells
ERp46 is localized in the ER and is suggested to act as a chaper-
one. About 20% of endogenous ERp46 are found at the plasma
membrane suggesting that this protein may have additional func-
tions. ERp46 interacts with amino acids 1–70 in the N-terminal tail
of AdipoR1. This sequence is not found in AdipoR2 and AdipoR2
does not form a complex with ERp46. Knock-down of ERp46 in-
creases AdipoR1 in the plasma membrane while ER levels are not
affected suggesting that ERp46 may regulate AdipoR1 surface
abundance by retaining this protein in the ER. Interestingly,
ERp46 knock-down also increases AdipoR2 in the ER and plasma
membrane fractions by a so far unknown mechanism [64].
In HeLa cells where ERp46 has been knocked-down adiponec-
tin-mediated phosphorylation of AMPK is increased whereasphosphorylation of p38 MAPK is impaired. These ﬁndings indicate
that activation of AMPK and p38 MAPK are independent down-
stream effects of adiponectin at least in HeLa cells. It is suggested
that ERp46 may have a role in AdipoR1 trafﬁcking and/or endocy-
tosis and this may affect signalling pathways eventually localized
to different compartments [64].
14. Conclusion
The identiﬁcation of APPL1 as a downstream adaptor protein
that associates with AdipoR1 and AdipoR2 considerably adds to
further elucidate adiponectin signal transduction pathways.
CK2b, ERp46 and RACK1 also bind to AdipoR1 and different recep-
tor complexes may be formed. However, it has to be stressed that
the function of these proteins has been mainly or even exclusively
analysed with respect to AdipoR1.
These recent ﬁndings raise several new questions: Are addi-
tional proteins recruited to adiponectin receptor complexes espe-
cially when considering the multiple proteins that may associate
with APPL1, CK2b and RACK1? Are there more proteins that di-
rectly bind adiponectin receptors? Do these proteins alter adipo-
nectin receptor stability or internalization? Is complex formation
impaired in obesity or metabolic diseases related to obesity? Is
the expression/localization of these proteins affected by obesity
or by commonly used drugs to treat diabetic patients?
Answers to these and related questions will contribute to re-
solve how this multifunctional adipokine exerts its beneﬁcial roles.Conﬂict of interest
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